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ABSTRACT
UDP-sugars, which are indispensable for protein glycosylation
reactions in cellular secretory pathways, also act as important
extracellular signaling molecules. We discuss here the broadly
expressed P2Y14 receptor, a G-protein–coupled receptor
targeted by UDP sugars, and the increasingly diverse set of
physiologic responses discovered recently functioning down-
stream of this receptor in many epithelia as well as in immune,
inflammatory, and other cells.
Introduction
UDP-sugars are key components of glycosylation reactions
in the lumen of the endoplasmic reticulum (ER) and Golgi
apparatus, and they also are important extracellular signal-
ing molecules acting as potent agonists of the broadly
expressed P2Y14 receptor (P2Y14R) (Harden et al., 2010).
The P2Y14R is activated by UDP-glucose, UDP-galactose,
UDP-N-acetylglucosamine, and other UDP-sugars. UDP also
acts as an agonist on this receptor, but ATP, UTP, or other
naturally occurring diphosphate or triphosphate nucleotides
have no P2Y14R activity (Chambers et al., 2000; Carter et al.,
2009; Harden et al., 2010). The P2Y14R is a subtype in the
eight-member family of nucleotide-activated P2Y receptors,
which are all G-protein–coupled receptors (GPCRs) (Ralevic
and Burnstock, 1998; Abbracchio et al., 2006; von Kugelgen
andHarden, 2011). These receptors can be subclassified based
on sequence and cell signaling response similarities into two
subgroups, the P2Y12 receptor–like and the P2Y1 receptor–
like subgroups. The P2Y14R is amember of the P2Y12 receptor–
like subgroup, which also includes the ADP-activated P2Y12
and P2Y13 receptors. An orphan GPCR, GPR87, with high
homology to the P2Y14R, also exists in the P2Y12-like subfamily of
receptors. These GPCRs share.40% primary sequence identity,
and all three couple to the Gi family of heterotrimeric G proteins.
They exhibitmuch lower sequence identity (,25%)with theP2Y1
receptor–like subgroup, which includes the ADP-activated P2Y1
receptor, the UTP/ATP-activated P2Y2 receptor, the UTP-
activated P2Y4 receptor, the UDP-activated P2Y6 receptor
and the ATP-activated P2Y11 receptor. All members of the
P2Y1 receptor–like subgroup couple to heterotrimeric pro-
teins of the Gq family and activate phospholipase C.
Mechanisms of Release and Metabolism of
Nucleotide Sugars
The initial characterization of the P2Y14R as a UDP-sugar–
activated receptor of widespread tissue distribution (Chambers
et al., 2000; Lee et al., 2003; Moore et al., 2003; Skelton et al.,
2003) suggested that nucleotide sugars are released from
cells in a regulated manner to accomplish autocrine/paracrine
signaling functions. Furthermore, functional studies over-
expressing recombinant P2Y14R in null cell lines revealed
the presence of endogenous agonists in extracellular solu-
tions. Using a chimeric Ga-subunit (Gaq/i) that couples
Gi-linked GPCRs to phospholipase C-b, robust P2Y14R-
dependent inositol phosphate production was shown to occur
in COS-7 cells in the absence of added agonist. That is,
expression of the P2Y14R resulted in a large increase in basal
[3H]inositol phosphate levels that were further elevated by
the addition of UDP-glucose to the medium (Lazarowski et al.,
2003). The elevated levels of [3H]inositol phosphates observed
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in the absence of exogenous agonists were markedly reduced
by addition to the medium of Crotalus adamentus phospho-
diesterase, which hydrolyzes nucleotides and nucleotide
sugars; apyrase, which hydrolyzes nucleotides but not
nucleotide sugars, had no effect (Lazarowski et al., 2003).
Using highly sensitive radioenzymatic/high-performance
liquid chromatography–based methodology, UDP-glucose,
UDP-N-acetylglucosamine, and UDP-galactose were iden-
tified and quantified in extracellular solutions (Lazarowski
et al., 2003, 2010; Sesma et al., 2009).
Actual concentrations of UDP-sugars in the physiologic
extracellular milieu are not known owing to difficulties in
sampling the thin cell-surface liquid without causing cell
damage and uncontrolled nucleotide release. When assessed
together in diluted culture medium (300 ml/cm2 culture
surface), steady-state concentration values of UDP-glucose
and UDP-N-acetylglucosamine on various airway epithelial
cell types were similar (both in the 5–10 nM range) (Sesma
et al., 2009), and, as discussed later herein, they increased
considerably in response to environmental challenges, likely
attaining micromolar levels at the surface of stressed cells.
UDP-sugars are synthesized in the cytosol and translocated
into the lumen of the ER and Golgi apparatus where they serve
as donor substrates of glycosylation reactions (Abeijon and
Hirschberg, 1992; Berninsone andHirschberg, 1998). Vesicular
UDP-sugars cannot be transported back to the cytosol and thus
are likely delivered as cocargo with exported glycoconjugates
(Fig. 1). Several lines of evidence support this hypothesis.
Gene deletion of Yea4, a major UDP-N-acetylglucosamine
transporter in Saccharomyces cerevisiae, resulted in im-
paired release of this nucleotide sugar and was associated
with reduced production of chitin, an acetylglucosamine-rich
component of the yeast wall. Complementation of yea4-
deficient cells with yea4 restored UDP-N-acetylglucosamine
release and chitin formation (Sesma et al., 2009). Similarly,
overexpression of the human UDP-N-acetylglucosamine
transporter HFRC1/SLC35D2 in bronchial epithelial cells
resulted in enhanced release of UDP-N-acetylglucosamine
and enhanced cell-surface expression of acetylglucosamine-
containing glycans (Sesma et al., 2009). Studies with mucin-
producing goblet epithelial cells indicated that UDP-glucose
release was associated with mucin secretion. For example, 1)
goblet-like Calu-3 cells exhibited Ca21-regulated exocytosis of
mucin granules, which was accompanied by enhanced release
of UDP-glucose (Kreda et al., 2007); and 2) both mucin
secretion and UDP-glucose levels increased concurrently in
human bronchial epithelial cell cultures that were induced to
develop goblet (mucous) cell metaplasia (Okada et al., 2011).
Lastly, 1321N1 human astrocytoma cells exhibit both consti-
tutive and protease-activated receptor 1–promoted release of
UDP-glucose, which were Ca21-dependent and markedly
reduced by brefeldin A1, a fungal metabolite that disrupts
retrograde movements along the secretory pathway (Kreda
et al., 2008).
Collectively, these observations suggest that the secretory
pathway is a major contributor to the cellular release of UDP-
sugars (Fig. 1). However, nonvesicular mechanisms that
contribute to the cellular release of ATP in many cell types
also could be involved in the release of UDP-sugars. For
example, caspase 3-mediated proteolytic irreversible activa-
tion of plasma membrane pannexin 1 channels resulted in
robust release of cytosolic ATP, as well as ADP, AMP, and
UTP, from apoptotic lymphocytes (Elliott et al., 2009; Chekeni
et al., 2010; Boyd-Tressler et al., 2014). These data suggest
that the pannexin 1 pore exhibits no specificity toward
nucleotide species. Thus, it is conceivable that, at least in
apoptotic cells, cytosolic UDP-glucose is released together
with adenine and uracil nucleotides via pannexin 1.
It is worth noting that, in most cases where regulated
nucleotide release was assessed, rates of UDP-glucose release
were markedly lower than ATP release rates, whereas steady-
state levels of UDP-glucose were often higher than ATP
levels. Differences in the rates of extracellular metabolism
account for this apparent discrepancy. UDP-sugars are not
metabolized by ecto-ATPase (ecto-nucleoside triphospho
diphosphohydrolase; NTPDase) activities, which are abun-
dantly expressed on the surface of most cell types (Zimmermann
et al., 2012). Instead, ecto-nucleotide pyrophosphatases
(ENPPs) break down UDP-sugars, according to the following
reaction:
UDP-sugar→UMP1 sugar-1P
ENPPs also metabolize nucleoside triphosphates (to nucleo-
side monophosphates 1 pyrophosphate), as well as nicotine
adenine dinucleotide, ADP-ribose, and dinucleoside polyphos-
phates. ENPP expression has been reported in several tissues
(Zimmermann et al., 2012), but only a few reports have
examined its possible action in extracellular metabolism of
UDP-sugars. UDP-[3H]glucose added as a radiotracer to
confluent cultures of 1321N1 human astrocytoma cells was
metabolized at rates that were much lower than ATP
hydrolysis rates (Lazarowski et al., 2003). UDP-[3H]glucose
remained unchanged after a 1-hour incubation with purified
Fig. 1. Pathways for UDP-sugar release. UDP-glucose (UDPG) and other
UDP-sugars are synthesized in the cytosol and enter the secretory
pathway via ER/Golgi-resident SLC35 transporters, using UMP as
antiporter substrates. ER/Golgi UDP-sugars are used for glycosylation,
yielding UDP as a reaction product, and UDP is metabolized to UMP.
(i) Residual UDP-sugars in the ER/Golgi lumen are released as cargo via
the constitutive secretory pathway. (ii) Unlike ATP and UTP, UDP-sugars
are not predicted to be substrates of the vesicular nucleotide transporter
(VNUT), but Golgi-derived vesicles are a source of UDP-sugars in
specialized granules susceptible to Ca2+-regulated exocytosis. Not shown:
Golgi UDP is released with UDP-sugars. Whether pannexin 1 mediates
the release of cytosolic UDP-sugars is not known. PPi, pyrophosphate;
G-1P, glucose-1P.
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human neutrophils (Sesma et al., 2012) or primary cultures of
human airway epithelial cells (Lazarowski, unpublished),
whereas [3H]ATP was completely hydrolyzed.
The high stability of UDP-glucose on airway epithelia and
potentially other tissues exhibiting regulated release of UDP-
sugars provides a mechanism by which these molecules could
accumulate in extracellular environments at pathophysiolog-
ically relevant levels. For example, UDP-glucose and UDP-N-
acetylglucosamine concentrations in diluted bronchioalveolar
lavages from patients with chronic lung obstruction and
inflammation reached the 200–400 nM range. As discussed
further in subsequent sections of this article, these observa-
tions suggest a link between local UDP-glucose release and
inflammation.
Targeting of the P2Y14R by Native Agonists and
High-Affinity Molecular Probes
The work of Chambers and colleagues (Chambers et al.,
2000) led to the realization that the orphan receptor GPR105,
now P2Y14R, is activated by nucleotide sugars with a relative
potency order ofUDP-glucose.UDP-galactose.UDP-glucuronic
acid . UDP-N-acetylglucosamine, and all these molecules
exhibited potencies in the 0.1–1.0 mM range of concentrations.
One potential caveat from this and additional early studies
was that they were accomplished using overexpressed G-protein
a-subunits, either with Ga16, which mediates coupling of
essentially all GPCR to phospholipase C-b isozymes, or with
the engineered protein, Gaq/i, which selectively couples Gi-linked
GPCR to activation of phospholipase C-b (Chambers et al., 2000;
Freeman et al., 2001; Lazarowski et al., 2003; Fricks et al., 2008).
Nonetheless, results from work studying the agonist selectivity
of the P2Y14R in cell systems in which it coupled through native
Gi heterotrimers to promote inhibition of adenylyl cyclase
confirmed the nucleotide sugar selectivity established by
Chambers and coworkers; that is, UDP-glucose is the most
potent agonist, but the activities of other nucleotide sugars
are within an order of magnitude (Fricks et al., 2009).
The studies of Carter and coworkers (Carter et al., 2009)
examining P2Y14R-dependent activities measured down-
stream of natively expressed Gi also revealed that UDP is
a very potent agonist of the P2Y14R. Indeed, this nucleotide
was 5-fold more potent than UDP-glucose in studies with
several different cell lines. Although direct comparisons have
not been published, it is unlikely that the concentration of
extracellular UDP approaches that of UDP-sugars under
most physiologic and pathologic conditions. UDP generated in
the ER/Golgi as a product of glycosylation reactions is
predicted to be either degraded to UMP by Golgi resident
UDPase or released with UDP-sugars via vesicle exocytosis;
UDP also is generated extracellularly from the hydrolysis of
released UTP; however, cell surface NTPDases rapidly
metabolize UDP but not UDP-sugars. Thus, we discuss the
P2Y14R as a nucleotide sugar-activated GPCR with the
realization that UDP may also play an important, albeit not
yet clearly established, role in its physiologic regulation.
Although nucleotide sugars are potent P2Y14R agonists
that are present at receptor-activating concentrations in
extracellular medium, the existence of other physiologic
agonists of this receptor cannot be entirely ruled out. The
realization that at least one orphan GPR87 with high (∼47%)
homology to the P2Y14R exists in the P2Y12-like subclass is
not inconsistent with this possibility.
Both synthetic agonists and high-affinity competitive antag-
onists have been developed that selectively target the P2Y14R
(Table 1). For example, 2-thio-UDP-glucose (MRS2690) exhib-
its 30-fold greater potency for the P2Y14R than does UDP-
glucose (Ko et al., 2007, 2009). Several analogs of UDP also
have been developed that exhibit high potency at the P2Y14R
(Das et al., 2010). These include a,b-difluoromethylene-UDP
(MRS2802) and a,b-methylene-2-thio-UDP (MRS2905). The
importance of these molecules lies in their selectivity for
activation of the P2Y14R at concentrations that are inactive at
the UDP-activated P2Y6 receptor, as well as at other P2Y
receptors (Carter et al., 2009; Das et al., 2010).
Black and coworkers applied high-throughput screens to
identify dihydropyridopyrimidine (Guay et al., 2011) and
naphthoic acid (Gauthier et al., 2011) compounds as potential
P2Y14R antagonists. Analogs of each type of molecule subse-
quently were synthesized. Whereas dihydropyridopyrimidine
derivatives appeared to be noncompetitive antagonists of the
P2Y14R, the naphthoic acid derivatives inhibited [
3H]UDP
binding, suggesting antagonism of the orthosteric ligand
binding site of the receptor (Gauthier et al., 2011; Robichaud
et al., 2011). Problems with high-affinity binding to serum
proteins observed with several of these naphthoic acid
analogs were partially circumvented in the analog PPTN
[4-((piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-
naphthoic acid] that retained activity as a P2Y14R antagonist.
A prodrug based on PPTN also was developed to increase
bioavailability. Barrett et al. (2013) illustrated that PPTN is
indeed a high-affinity (KB 5 ∼400 pM) competitive antagonist
of the P2Y14R that exhibits no activity at the other seven P2Y
receptors at concentrations as high as 10 mM. PPTN was
applied subsequently to selectively block P2Y14R-dependent
responses. Thus, UDP-glucose promoted chemotaxis of hu-
man neutrophils (Barrett et al., 2013), P2Y14R agonist-
promoted release of b-hexosaminidase from human LAD2
mast cells (Gao et al., 2013), and promoted contractile effects
on porcine vascular smooth muscle (Alsaqati et al., 2014); all
were antagonized by low concentrations of PPTN. Several
other potential P2Y14R inhibitors have been reported by
Hamel and coworkers (Hamel et al., 2011).
Jacobson and colleagues examined a series of chain-elongated
alkynyl or amino derivatives of PPTNwith the goal of generating
a fluorescent probe for the P2Y14R (Kiselev et al., 2014). Many of
these retained activity at the P2Y14R, and an Alexa Fluor 488
(AF488)–derivatized version (MRS4174) of one of these exhibited
remarkably high (Ki 5 80 pM) binding activity. This molecule
selectively labeled the P2Y14R in live cells as quantified by flow
cytometry.
P2Y14R-Mediated Cell Signaling Responses
The idea that the P2Y14R is Gi-coupled was initially
suggested by the observation that UDP-glucose stimulated
[35S]GTPgS binding in membranes from P2Y14R-expressing
HEK293 cells, which was inhibited by pretreatment of cells
with pertussis toxin (Chambers et al., 2000). As discussed
already, this notion was further supported by studies using
chimeric Gaq/i proteins that translate Gi signaling into
phospholipase C-b activation (Freeman et al., 2001; Lazarowski
et al., 2003; Fricks et al., 2008). Fricks and coworkers
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(Fricks et al., 2009) showed that the human P2Y14R indeed
couples through natively occurring Gi (Fig. 2) and that its
activation results in robust inhibition of the classic effector of
Gi, adenylyl cyclase.
Gi heterotrimers are expressed at high levels in plasma
membranes compared with other Ga-subunits and largely,
but not entirely, signal through the release of Gbg-subunits
from the heterotrimer (Smrcka, 2008). Thus, Gbg-activated
effectors can be expected to be activated downstream of
activated P2Y14R, although data directly illustrating responses
from most of these are not available. Activation of mitogen-
activated protein kinase (MAPK) signaling pathways pre-
dictably occurs downstream of Gi-coupledGPCRs (Crespo et al.,
1994), and therefore it is not surprising that P2Y14R-dependent
phosphorylation of MAPKs also is well established. UDP-
glucose promoted extracellular signal–regulated kinase (ERK)
1/2 phosphorylation in P2Y14R-expressing human embryonic
kidney (HEK293) cells with a potency similar to that observed
in the same cells for inhibition of adenylyl cyclase and by
a mechanism that was blocked by pertussis toxin pretreatment
(Fricks et al., 2009). Differentiation of undifferentiated HL-60
promyelocytic leukemia cells results in expression of P2Y14R
mRNA (Fricks et al., 2009), and whereas the effects of UDP-
glucose were not observed in undifferentiated cells, ERK1/2
phosphorylation occurred in response to UDP-glucose in
differentiated HL-60 cells. Again, pertussis toxin pretreatment
blocked UDP-glucose–promoted ERK activation. Activation of
ERK also was reported for UDP-glucose–treated human
neutrophils (Scrivens and Dickenson, 2006).
Sesma and coworkers showed that UDP-glucose promotes
activation of Rho and chemotaxis of human neutrophils, and
the latter was blocked by inhibitors of Rho kinase. Activation
of Rho and chemotaxis also occurred in differentiated but not
wild-type HL-60 cells. These responses were absent after
pretreatment of differentiated HL-60 cells with pertussis
toxin and were also inhibited by pharmacologic inhibitors
of phosphatidylinositol (PtdIns)-3-kinase or Rho kinase.
PtdIns-3-kinase is a well established effector of Gbg (Stephens
et al., 1994), and this work suggests that neutrophils
respond to P2Y14R activation in a pathway that involves
Gbg-dependent activation of PtdIns-3-kinase, plasma mem-
brane recruitment of an exchange factor for Rho, production
of GTP-Rho, actin cytoskeleton rearrangement, and enhanced
neutrophil shape change and locomotion. Additional effec-
tors of Gbg (Fig. 2) that may also function downstream of
activated P2Y14R include K
1 channels, GPCR kinase 2 and 3,
phospholipase C-b2 and -b3, SNAP-25, and P-Rex 1 Rac
GEF (Smrcka, 2008).
Physiologic and Pathophysiologic
Consequences of P2Y14 Receptor Activation
Whereas several rigorous studies indicate a role of P2Y14R
in UDP-sugar–promoted physiologic responses, unambiguous
evidence of the involvement of the P2Y14R in cellular functions
often has been difficult to assimilate. For example, although
commercial sources of UDP-glucose induced inflammatory effects
in N9 microglia, this action was observed only with bacterially
derived, but not synthetic, UDP-glucose, and other nucleotide
sugars had no effect (Brautigam et al., 2008). As pointed out
by the authors, these results likely reflected an effect that is
due to a contaminant of UDP-glucose solutions and were
independent of P2Y14R activation (Brautigam et al., 2008).
Scrivens and Dickenson reported that UDP-glucose promoted
inhibition of cAMP formation in forskolin-stimulated human
neuroblastoma SH-SY5Y cells, but they noted that reverse
transcription polymerase chain reaction analysis showed no
P2Y14R mRNA expression in these cells (Scrivens and
Dickenson, 2005b). In another report, intraperitoneal admin-
istration of high concentrations of UDP-glucose to wild-type
mice resulted in an increase in gastric emptying, but this
effect was retained in P2Y14R knockout mice (Bassil et al.,
2009). Thus, caution should be taken in interpreting studies of
UDP-sugar–evoked responses that are not validated by data
with receptor gene deletion or knockdown or by selective
TABLE 1
Agonists and antagonists of the P2Y14R
Molecule Potency
Natural agonistsa UDP-glucose EC50 = 132 nM
UDP EC50 = 33 nM
Selective synthetic agonistsb,c 2-thio-UDP-glucose (MRS2690) EC50 = 49 nM
a,b-methylene-2-thio-UDP (MRS2905) EC50 = 0.92 nM
Selective competitive antagonistd PPTN KB = 400 pM
aEC50 values are from experiments measuring inhibition of cAMP accumulation in P2Y14R-expressing CHO cells
(Carter et al., 2009).
bValues are from experiments measuring inositol phosphate accumulation in Cos-7 cells expressing the human P2Y14R
and Gaq/i (Ko et al., 2007).
cValues are from experiments measuring inhibition of cAMP accumulation in P2Y14R-expressing HEK293 cells (Das
et al., 2010).
dKB for PPTN was obtained in Schild analyses measuring antagonism of UDP-glucose–promoted inhibition of cyclic
AMP accumulation in P2Y14R-expressing CHO cells (Barrett et al., 2013).
Fig. 2. Signaling pathways associated with P2Y14R activation. The
P2Y14R couples to Gi, thus promoting Gai- and Gbg-mediated inhibition
of adenylyl cyclases 1, 3, 5, 6, 8, and 9. Additional direct and indirect
effectors of Gbg include K+ channels (GIRK), phosphatidylinositol
3-kinase-g, GPCR kinase 2 and 3, and phospholipase C b2 and b3, P-rex1
Rac GEF, and SNAP-25. Rho, MAPKs, and potentially other effectors not
listed represent examples of signaling proteins that are also activated
downstream of Gbg.
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pharmacologic antagonism. Conversely, weak or no responses
to exogenous UDP-glucose in tissues known to express
P2Y14R mRNA could be due to receptor desensitization or
elevated baselines caused by cellular UDP-sugar release, low
receptor protein abundance, robust ENPP activity, or a com-
bination of these factors. Caution also should be taken when
analyzing results from P2Y14R-targeted mice, as epigenetic
changes may contribute to phenotypes not necessarily
associated with P2Y14R lack of function. Further, antisera
purportedly generated against P2Y14R have been used to
assess receptor protein expression in various tissues, but
strict validation of these antibodies has not been provided.
Bearing in mind these concerns, evidence supporting physi-
ologic or pathophysiologic roles for the P2Y14R is discussed
below.
Immune or Inflammatory Cells
P2Y14R transcripts are robustly expressed in leukocytes
and other immune/inflammatory cells and are upregulated in
the rat brain after immunologic challenge with lipopolysac-
charide (Moore et al., 2003), suggesting that the P2Y14R plays
an important role in immune or inflammatory responses.
Monocytes and Macrophages. Macrophages play im-
portant roles in both innate and adaptive immunity and are
critical effector cells in proinflammatory processes. The
release of proinflammatory cytokines from macrophages in
obesity is associated with insulin receptor phosphorylation
and insulin resistance (Olefsky and Glass, 2010), and a recent
study suggests contribution of the P2Y14R to this process (Xu
et al., 2012). Specifically, 1) wild-type mice developed severe
glucose intolerance when fed a high-fat diet (HFD), whereas
P2Y14R knockout mice were protected from HFD-induced
glucose intolerance; 2) P2Y14R-deficient mice exhibited
improved systemic insulin sensitivity after a HFD and
enhanced insulin action in adipose tissue, liver, and skeletal
muscles; 3) after a HFD, P2Y14R knockout mice exhibited
a reduced number of macrophages in the liver compared with
wild-type animals; 4) P2Y14R-deficient monocytes showed
reduced migration to the liver of HFD-fed wild-type mice; 5)
plasma levels of UDP-glucose were elevated 4-fold in HFD-fed
animals compared with controls; 6) UDP-glucose–promoted
migration of bone marrow–derived macrophages in vitro was
reduced with P2Y14R knockout-derived bone marrow–derived
macrophages; and 7) transplantation of P2Y14R-deficient
bone marrow cells reestablished insulin sensitivity in HFD-
fed wild-type mice. Taken together, these results suggest that
UDP-glucose released from liver cells in obese states, possibly
via hepatocellular apoptosis (Wang et al., 2008), acts as
a chemoattractant to recruit monocytes/macrophages, leading
to liver inflammation and insulin resistance.
Neutrophils. Polymorphonuclear neutrophils (PMNs)
constitute the first line of defense to eradicate bacterial
infection. Circulating PMNs are among the peripheral human
cell types that most abundantly expresses P2Y14R mRNA
(Moore et al., 2003), but initial attempts to identify P2Y14R-
promoted responses in neutrophils were inconclusive. UDP-
glucose promoted a modest inhibition of forskolin-stimulated
cAMP formation in neutrophils, but other UDP-sugars had no
effect (Scrivens and Dickenson, 2006). UDP-glucose also
evoked a modest increase in ERK phosphorylation in these
cells, but this response was observed only at high micromolar
concentrations and was not mimicked by other UDP-sugars;
neutrophil elastase secretion was not enhanced by UDP-
glucose (Scrivens and Dickenson, 2006). Lastly, neutrophils
exhibited no migration response toward UDP-glucose when
assessed via the classic transwell filter staining method
(Arase et al., 2009).
Subsequent studies have provided more compelling evi-
dence for functional expression of P2Y14R in neutrophils. As
discussed already, expression of native P2Y14R is induced
during differentiation of neutrophil-like HL-60 human mye-
loid leukemia cells, and UDP-glucose and other UDP-sugars
promoted activation of MAPK and Rho signaling in
neutrophil-differentiated (but not in undifferentiated) HL60
cells in a pertussis toxin-sensitive manner (Fricks et al., 2009;
Sesma et al., 2012). UDP-glucose–promoted migration of
differentiated HL60 cells was observed using a modified
Boyden chamber under conditions that quantified chemotaxis
of fluorescently labeled cells with high sensitivity. UDP-
glucose also promoted Rho kinase-dependent chemotaxis of
freshly isolated human neutrophils (Sesma et al., 2012), and
this response was abolished when the P2Y14R antagonist
PPTN was added to the PMN suspension (Barrett et al.,
2013).
Observation of P2Y14R-dependent PMN migration and
potentially additional neutrophil functions could be relevant
to chronic inflammatory lung diseases associated with elevated
levels of extracellular UDP-sugars in the lung (Sesma et al.,
2009). As discussed further below, an additional mechanism by
which UDP-sugars may evoke PMN recruitment in the lung
involves activation of P2Y14R on epithelial cells and release of
IL-8 (Muller et al., 2005).
Mast Cells. Mast cells are bone marrow–derived immune
effector cells that play important roles in allergic diseases
such as bronchial asthma, rhinitis, anaphylaxis, and urticaria.
IgE (Fc)-stimulated mast cells release histamine, proteases,
and other hydrolytic activities from secretory granules and
generate eicosanoid mediators that promote the production and
secretion of proinflammatory cytokines and chemokines.
Whether the P2Y14R is expressed in primary mast cells is not
known, but studies withmast cell–like cell lines suggest that the
P2Y14R is a mediator of degranulation in these cells. P2Y14R
mRNA was abundantly present in RBL-2H3 rat mast cells, and
UDP-glucose, as well as the potent P2Y14R agonist 2-thio-UDP-
glucose, enhanced the release of b-hexosaminidase, an indicator
of granule secretion (Gao et al., 2013). Hexosaminidase secretion
was reduced by knocking down the P2Y14R via small interfering
RNA (siRNA). Similar results were reported using the human
bone marrow–derived mast cell line LAD2, and incubation of
these cells with PPTN (10 mM) resulted in reduced UDP-
sugar–potentiated C3a-promoted hexaminidase secretion (Gao
et al., 2013).
Dendritic Cells. P2Y14R mRNA was detected at high
levels in immature human monocyte-derived dendritic cells
that mature and migrate to sites of inflammation (Skelton
et al., 2003). Exposure of immature monocyte-derived den-
dritic cells to UDP-glucose resulted in transient mobilization
of Ca21 and increased expression of CD86, suggesting that the
P2Y14R regulates dendritic cell maturation (Skelton et al.,
2003).
Lymphocytes. T-lymphocytes express P2Y14R transcripts
(Moore et al., 2003), and UDP-glucose was reported to cause
a modest decrease in cAMP levels in these cells as well as to
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inhibit T-cell proliferation in response to anti-CD3 antibody or
interleukin 2 (Scrivens and Dickenson, 2005a).
Hematopoietic Stem Cells
The P2Y14R was reported to be selectively expressed in
subpopulations of primitive bone marrow hematopoietic stem
cells (HSCs), suggesting a role for this receptor in bone
marrow cell localization and compartmentalization (Lee et al.,
2003). Subsequent studies illustrated that subcutaneous
administration of UDP-glucose to mice resulted in enhanced
mobilization of HSCs into the peripheral blood and spleen
(Kook et al., 2013a). In a separate study (Kook et al., 2013b),
the authors reported that subcutaneous administration of
UDP-glucose to in utero-irradiated pregnant mice attenuated
the effect of irradiation on the growth and mortality rates of
the offspring. Whether these effects of UDP-glucose reflected
a P2Y14R-dependent mechanism is not known. Strikingly,
prenatal irradiation of P2Y14R knockout mice resulted in
enhanced growth and survival rates compared with wild-type
mice (Kook et al., 2013b).
In a more recent study, this group showed that HSCs from
P2Y14R knockout mice exhibit increased senescence, a state of
permanent irreversible growth arrest in response to aging,
radiation, chemotherapy, and other environmental stresses
(Cho et al., 2014). Enhanced senescence was associated
with increased reactive oxygen species, elevated p16INK4a
expression, and reduced hyperphosphorylation of the
retinoblastoma protein pRb, an inducer of cell senescence.
Treatment of wild-type cells with pertussis toxin recapit-
ulated the phenotype observed in P2Y14R-deficient mice.
Furthermore, primitive HSCs lacking P2Y14R exhibited
impaired ability to restore hematopoiesis in irradiated
mice. These observations suggest that the P2Y14R on stem
or progenitor hematopoietic cells promotes regenerative
responses after injury (Cho et al., 2014; Garrison and Rossi,
2014).
Osteoclast Differentiation
Osteoclasts are multinucleated cells that develop from the
fusion of bone marrow–derived monocyte/macrophage pro-
genitors; receptor activator of nuclear factor-kB ligand
(RANKL) is a key regulator of osteoclast differentiation and
function (Teitelbaum, 2000). Using tartrate-resistant acid
phosphatase as an osteoclast gene expression marker, Lee
and coworkers showed that the P2Y14R is selectively
transcribed during RANKL-induced osteoclastogenesis (Lee
et al., 2013). P2Y14R siRNA markedly decreased P2Y14R
protein expression and caused a .50% reduction of RANKL-
induced osteoclast formation, suggesting that P2Y14R expres-
sion is required for the osteoclast differentiation program.
This hypothesis was further supported by the observation
that RANKL-induced osteoclast formation is markedly po-
tentiated by coincubating bone marrow–derived monocyte/
macrophage precursors with UDP-glucose, UDP-galactose,
UDP-N-acetylglucosamine, or UDP-glucuronic acid (Lee
et al., 2013). In line with this work, the above-mentioned
study of Kook and colleagues indicated that UDP-glucose–
stimulated hematopoietic stem cell mobilization was associ-
ated with enhanced bone marrow RANKL expression and
enhanced osteoclastogenesis (Kook et al., 2013a).
Glia and Astrocytes
Initial reports indicated broad expression of P2Y14R mRNA
in various areas of the brain (Chambers et al., 2000), and
strong immunohistochemical staining of brain astrocytes and
glia with an affinity-purified P2Y14R antiserum was sub-
sequently reported (Moore et al., 2003). Cultured rat primary
astrocytes and murine microglia N9 cells express P2Y14R
mRNA, and addition of 100 mMUDP-glucose to rat astrocytes
resulted in transient elevation of intracellular calcium
(Fumagalli et al., 2003; Bianco et al., 2005). More recently,
Kinoshita et al. (2013) reported that UDP-glucose–promoted
Ca21 signaling was reduced by ∼50% in astrocytes transfected
with P2Y14R siRNA, although the extent of P2Y14R suppres-
sion was not reported. In the absence of exogenous agonists,
P2Y14R siRNA-transfected cells displayed increased release
of tumor necrosis factor-a (TNFa) and expression of matrix
metalloprotease-9 (MMP-9), suggesting that astrocyte remod-
eling events are suppressed by constitutively active P2Y14R
(Kinoshita et al., 2013).
Innate Mucosal Immunity
Female Reproductive Tract Epithelia. P2Y14R mRNA
is highly expressed in the surface epithelium of the female
reproductive tract, and immunohistochemical studies also
were consistent with prominent expression of this receptor in
epithelium but not stromal tissues (Arase et al., 2009).
Similarly, UDP-glucose caused a concentration-dependent
increase in interleukin-8 (IL-8) secretion in primary cultures
of human glandular cells but had no effect on stromal cells
(Arase et al., 2009). Ishikawa endometrial epithelial cells also
express P2Y14R, and UDP-glucose caused an increase in IL-8
production and secretion in these cells, which was reduced by
pretreatment of cells with pertussis toxin and by siRNA-
mediated knockdown of the P2Y14R. Conditioned medium
from UDP-glucose–stimulated Ishikawa cells exhibited neu-
trophil chemoattractant activity, which was blocked by a
neutralizing anti–IL-8 antibody (Arase et al., 2009).
Incubation of mouse uterine tissues with 10 nM UDP-
glucose resulted in enhanced expression of two functional
homologs of IL-8, MIP-2 and KC (Arase et al., 2009).
Surprisingly, the effect of UDP-glucose was not observed at
higher (1000 nM) concentrations, and UDP-N-acetylglucosamine
had no effect. Direct injection of UDP-glucose (but not saline) into
one horn of the mouse uterus in vivo induced MIP-2 and KC
protein. Importantly, induction of these two chemokines was
restricted to the endometrial luminal and glandular cells as
was observed with IL-8 in the human endometrium. Finally,
administration of UDP-glucose to mouse uterus resulted in
a ∼5-fold increase in the number of neutrophils present in
the endometrium after 48 hours, which was reduced by
sonoporation of P2Y14R siRNA into the mouse uterus (Arase
et al., 2009). Lipopolysaccharide also induced leukocytosis in
mouse uterus, and this effect was attenuated by P2Y14R
siRNA.
Arase and coworkers also noted that lipopolysaccharide
induced upregulation of P2Y14R in Ishikawa cells as well as in
mouse uterus, which is consistent with the observation of
P2Y14R upregulation in the human endometrium during
inflammation. For example, messages for the P2Y14R as well
as for IL-1b, IL-8, and TNF-a all were upregulated in
endometria from patients with pelvic inflammatory disease
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(Arase et al., 2009). Reports of P2Y14R mRNA upregulation in
themouse uterus after estradiol treatment of 7 days (Crabtree
et al., 2006, 2008) also suggest that P2Y14R expression may be
regulated by circulating hormone levels.
In sum, these studies strongly suggest that the P2Y14R
promotes innate mucosal immunity in the female reproduc-
tive tract by inducing IL-8.
Lung Epithelial Cells. P2Y14R mRNA is expressed in
primary cultures of human alveolar epithelial type 2 cells, as
well as in an human adenocarcinoma alveolar epithelial cell
line (A549 cells) and immortalized human bronchial epithelial
BEAS-2B cells (Muller et al., 2005). UDP-glucose dose-
dependently evoked Ca21 mobilization and IL-8 secretion in
A549 and BEAS-2 cells, and pertussis toxin abolished these
effects. Alveolar type II cells are located at the boundary
between the alveolar airspace and the interstitium, and
addition of UDP-glucose to primary alveolar type 2 cells
resulted in enhanced IL-8 secretion, suggesting that the
P2Y14R on type 2 cells senses UDP-sugars accumulating in
the alveolar space, potentially triggering neutrophil recruit-
ment via IL-8 secretion (Muller et al., 2005).
Gastrointestinal Functions
Message for the P2Y14R is widely expressed in the rodent
gastrointestinal tract (Chambers et al., 2000), with the
highest levels observed in the forestomach (Bassil et al., 2009).
UDP-glucose and UDP-galactose promoted concentration-
dependent increases in baseline muscle tension in isolated
forestomach longitudinal muscle preparations (Bassil et al.,
2009). The effects of UDP-glucose were lost in tissue isolated
from the p2y14 knockout mouse (generated by interrupting
the open reading frame of the P2Y14R with an IRES-LacZ-
polyA reporter expression cassette), and strong b-galactosidase
staining was observed in the muscularis externa of the
forestomach of these mice (Bassil et al., 2009). P2Y14R-
deficient mice exhibited no apparent alteration in gastric
clearance of a nutrient meal (Bassil et al., 2009). Interestingly,
using a similarly generated P2Y14R-deficient mouse model,
Meister and colleagues reported that robust b-galactosidase
activity was observed in subsets of smooth muscle cells
from the ileum to the colon, and excretion of orally admin-
istrated dextran blue in feces was delayed in P2Y14R
knockout mice compared with wild-type mice (Meister et al.,
2014). These observations suggest that P2Y14R function is
associated with meal passage throughout the entire gastroin-
testinal tract.
Endocrine Pancreas
Meister and coworkers also found high levels of P2Y14R
mRNA in the pancreas of wild-type mice, with robust
b-galactosidase expression in the islets as well as the exocrine
pancreas of P2Y14R-targeted mice; the cell type in which the
receptor is expressed was not identified (Meister et al., 2014).
Insulin immunostaining of pancreatic tissue was similar in
both genotypes, but glucose-promoted insulin secretion in
perfused islets was markedly reduced in P2Y14R-deficient
mice. P2Y14R knockout mice kept under a Western-type diet
(rich in fat and cholesterol) for 12 weeks exhibited reduced
serum insulin levels in response to glucose administration
compared with wild-type animals. Perfusion of wild-type
islets with UDP-glucose promoted no insulin secretion,
suggesting that the P2Y14R regulates functions that are
necessary but not sufficient to promote insulin granule
exocytosis. Transcriptome analysis of pancreatic islets in-
dicated that P2Y14R deletion resulted in downregulation of
more than 300 genes, including the glucose transporter
Slc2a2 and several components of the Ca21-triggered and
GPCR-modulated insulin release pathways (Meister et al.,
2014). In addition, more than 400 transcripts were upregu-
lated in these preparations. Notably, no differences in insulin
sensitivity were observed betweenWestern diet–fed wild-type
and P2Y14R-deficient mice (Meister et al., 2014), an observa-
tion that is in apparent conflict with those described by Xu
and colleagues with HFD-fed mice (Xu et al., 2012). The
discrepancy may reflect different contributions of liver in-
flammation to insulin sensitivity between the two mouse
models.
Vascular and Airway Tone
Vascular Tone. P2Y14R transcripts are localized in mid-
dle meningeal and rat aortic smooth muscle cells (Govindan
et al., 2010; Haanes and Edvinsson, 2014b). Meister and
collaborators found strong b-galactosidase staining in smooth
muscle cells of venous blood vessels as well as in a few
arteries, such as lung arteries and central nervous system
circulus arteriosus Willisii. P2Y14R-targeted mice exhibited
a mild increase in blood pressure and heart rates (Meister
et al., 2014).
Haanes and Edvinsson (2014a) reported that UDP-glucose
promoted contraction of mouse coronary arteries, and this
effect was reduced by pertussis toxin. High micromolar
concentrations of UDP-glucose were used to induce contrac-
tion of freshly excised arteries, but UDP-glucose potency
increased considerably in coronary arteries that were main-
tained in culture medium for 24 hours; all these responses
were reproduced with arteries isolated from P2Y2 receptor
knockout mice, ruling out the possibility that traces of ATP or
UTP in UDP-glucose solutions accounted for the observed
results (Haanes and Edvinsson, 2014a). The enhanced
potency of UDP-glucose effects on precultured coronary
arteries correlated with an enhanced immunohistochemistry
staining and increased intensity of a 70-kDa band onWestern
blots assessed with a commercial antibody against P2Y14R.
Results similar to those with coronary arteries were observed
with basilar arteries, except that in the latter, treatment with
pertussis toxin resulted in UDP-glucose–evoked relaxation
rather than contraction (Haanes and Edvinsson, 2014a). The
availability of P2Y14R antagonists and P2Y14R knockout
mouse models should now provide tools to more conclusively
define the involvement of the P2Y14R in UDP-glucose–
promoted contraction of coronary and basilar arteries.
Alsaqati and coworkers reported thatUDP-glucose (1–1000mM)
and the synthetic P2Y14R agonist MRS2690 (0.1–30 mM)
elicited vasoconstriction of porcine pancreatic arteries, and
the P2Y14R antagonist PPTN (10 mM) inhibited these
responses (Alsaqati et al., 2014). In contrast, UTP-promoted
contraction was not affected by PPTN. UDP-sugar–promoted
contraction was attenuated by removal of the endothelium as
well as by antagonists of endothelin ETA and thromboxane/
prostaglandin receptors and by inhibitors of intracellular
signaling (e.g., Ca21, Rho kinase). UDP-glucose (1 mM) and
MRS2690 (10 mM) promoted a decrease of cAMP formation in
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pancreatic arterial rings costimulated with forskolin and the
prostaglandin analog U46619 [(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-
3-hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic
acid]. By promoting endothelium-dependent artery contrac-
tion in the pancreas, the P2Y14R may influence pancreatic
functions by regulating blood flow into the pancreas.
Airway Tone. In addition to vascular and gastrointestinal
smooth muscles, Meister and coworkers observed P2Y14R
reporter expression (b-galactosidase) in smooth muscle cells
of bronchioles. In line with this P2Y14R expression pattern,
reduced lung resistance and increased dynamic compliance in
response to methacholine were observed in P2Y14R knockout
mice (Meister et al., 2014). These observations may be
relevant to altered airway responsiveness associated with
obstructive lung diseases.
Conclusions
Fifteen years have elapsed since the initial characterization
of the product of the orphan gene GPR105 (KIAA0001) as
P2Y14R, a Gi-coupled receptor potently activated by UDP-
sugars (Chambers et al., 2000). The abundant message
expression of the human P2Y14R in adipose tissue, stomach,
intestine, some brain regions, skeletal muscles, spleen, lung,
and heart suggests that released UDP-sugars fulfill impor-
tant extracellular signaling roles in these tissues. Realization
that mRNA for the GPR105 rat ortholog in brain and spleen is
regulated by immunologic challenge and that the P2Y14R
mRNA is also prominently expressed in peripheral inflam-
matory cells further suggests a role for this receptor in
immunity and inflammation (Chambers et al., 2000; Moore
et al., 2003).
Using P2Y14R gene deletion or downregulation approaches,
as well as newly developed highly selective P2Y14R agonists
and antagonists, considerable progress was achieved during
recent years to further support and expand those early
observations. The work of Arase et al. (2009) successfully
targeting P2Y14-R expression by introducing siRNA in mouse
uterus in vivo revealed a mechanism relevant to mucosal
inflammation (i.e., UDP-glucose–promoted P2Y14R-mediated
IL-8 release and neutrophil recruitment in the uterus).
Studies by Sesma and coworkers (2012) and Barrett and
coworkers (2013) support an additional scenario for UDP-
sugar–promoted neutrophil inflammation (i.e., direct acti-
vation of the neutrophil P2Y14R).
ATP released from stressed cells acts as a “find-me” signal
to recruit macrophages at the site of injury (Elliott et al., 2009;
Chekeni et al., 2010), and the work by Xu and colleagues
(2012) suggests a similar role for UDP-glucose. That is, HFD-
induced macrophage inflammation in the liver was attenu-
ated in P2Y14R-targeted mice. Moreover, blood levels of
UDP-glucose were elevated in HFD-fed mice, and UDP-
glucose promoted chemotaxis of wild-type mice but not P2Y14-
deficient monocytes.
In addition to promoting recruitment of circulating neu-
trophils and monocytes, UDP-glucose induced the mobiliza-
tion and enhanced relocation to extramedullary organs of
a subset of bone marrow stem cells (Kook et al., 2013a).
P2Y14R-mediated hematopoietic stem cell mobilization pro-
vides a potential tool to improve the efficiency and outcome of
hematopoietic peripheral stem cell transplantation. Further-
more, primitive hematopoietic stem cells lacking P2Y14R
exhibited impaired ability to restore hematopoiesis in
irradiated mice, suggesting that the P2Y14R on progenitor
stem cells promotes regenerative responses after injury (Cho
et al., 2014).
P2Y14R-targeted mice have been useful to identify func-
tions of this receptor that are associated with gastrointestinal
and digestive functions: 1) UDP-glucose–promoted baseline
muscle tension in isolated forestomach longitudinal muscle
preparations was abolished in P2Y14 knockout mice (Bassil
et al., 2009); 2) P2Y14R knockout mice exhibited delayed
excretion of orally administrated dextran blue in feces
(Meister et al., 2014), suggesting that the P2Y14R regulates
meal passage through the gastrointestinal tract; and 3)
P2Y14R knockout mice exhibited impaired glucose tolerance
and deficient insulin secretion in response to glucose (Meister
et al., 2014).
Realization that the P2Y14R is abundantly expressed in
subsets of smooth muscle cells of the vasculature and airways
and that P2Y14R-deficient mice exhibited increased blood
pressure and heart rates as well as reduced lung resistance
and increased dynamic compliance in response to methacho-
line (Meister et al., 2014) suggest important additional areas
of potential pharmacologic intervention.
Indeed, potent and selective P2Y14R antagonists (e.g.,
PPTN) are now available (Kiselev et al., 2014), and one of
them, PPTN, significantly reduced UDP-glucose–promoted
neutrophil chemotaxis, mast cell degranulation, and pancre-
atic artery contraction. This finding suggests novel strategies
TABLE 2
Proposed physiologic effects of P2Y14R activation
P2Y14R-Associated Responses References
Regulation of dendritic cell maturation Skelton et al., 2003
Inhibition of T-lymphocyte proliferation Scrivens and Dickenson, 2005a
Recruitment of monocytes and macrophages in inflammation Xu et al., 2012
Stimulation of neutrophil chemotaxis Sesma et al., 2012; Barrett et al., 2013
Enhancement of degranulation of mast cells Gao et al., 2013
Promotion of hematopoietic regenerative responses Cho et al., 2014
Regulation of osteoclast differentiation Lee et al., 2013; Kook et al., 2013a
Regulation of astrocyte remodeling Kinoshita et al., 2013
Stimulation of innate mucosal immunity in the female reproductive tract Arase et al., 2009
Promotion of lung inflammation Muller et al., 2005
Regulation of gastrointestinal muscle contraction and meal passage Bassil et al., 2009; Meister et al., 2014
Regulation of insulin secretion Meister et al., 2014
Regulation of smooth muscle contraction in some vascular beds Meister et al., 2014; Haanes and Edvinsson, 2014a; Alsaqati
et al., 2014
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for the treatment of inflammation and, potentially, other
disorders associated with the increasing number of P2Y14R-
regulated functions recently identified (Table 2).
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